Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 May-Jun;21(3):137-42.
doi: 10.1016/j.jdiacomp.2007.02.005.

Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes

Ildiko Lingvay  1 , Philip Raskin, Lidia S Szczepaniak
Affiliations
Clinical Trial

Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes

Ildiko Lingvay et al. J Diabetes Complications. 2007 May-Jun.

Abstract

Objective: Hepatic steatosis occurs in up to 78% of patients with type 2 diabetes. Studies evaluating the effect of metformin on hepatic steatosis are conflicting. Insulin is believed to be detrimental due to its lipogenic effect. Since insulin-metformin combination is commonly used for the treatment of diabetes, it is important to assess the effect of this combined therapy on hepatic steatosis. We evaluated the change in hepatic steatosis following the initiation of insulin and metformin in patients with type 2 diabetes.

Methods: Newly diagnosed treatment-naïve patients with type 2 diabetes had their hepatic triglyceride (TG) content measured by magnetic resonance spectroscopy at baseline and after 3 months of treatment with BiAsp 30 insulin, in combination with metformin. Insulin was administered twice daily and titrated to achieve normal capillary blood glucose levels. Metformin was titrated during the first month from 500 mg daily to 1000 mg bid.

Results: The average hepatic TG content in 19 enrolled subjects was 11.83+/-7.61% (range, 0.93-23.16%) and correlated with body mass index (r=.567). Three months of treatment reduced hepatic steatosis by 45%, with 75% of the study subjects achieving a normal level. The change in hepatic TG content was partially explained by changes in HbA1c (P=.006) and cholesterol (P=.003) levels.

Conclusions: The combined treatment with insulin and metformin significantly reduced hepatic steatosis in patients with newly diagnosed type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Individual hepatic triglyceride levels at baseline and after 3 months of treatment. Black lines = data on volunteers who completed the study (n=12), Black circles = data on volunteers who only had a baseline evaluation (n=7).
Figure 2
Figure 2
Scatter plot showing the correlation between baseline hepatic TG content and BMI (n=19).
See this image and copyright information in PMC

References

    1. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes & metabolism. 2000;26:98–106. - PubMed
    1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md. 2004;40:1387–1395. - PubMed
    1. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes care. 2006;29:1845–1850. - PubMed
    1. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Annals of internal medicine. 1997;126:137–145. - PubMed
    1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893–894. - PubMed

Publication types